MicroRNA-mediated down-regulation of HECTD2 expression has been proposed to drive androgen independence in prostate cancer (Sun et al. 2014), and more recently, HECTD2 copy number alterations were suggested as drivers in neuroblastoma patients (Suo et al. 2018). The gene discussed is HECTD2; the disease is neuroblastoma.